| Document |
Document Title |
|
WO/2024/094731A1 |
The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormalit...
|
|
WO/2024/094607A1 |
The present invention generally relates to the field of isotope labeled and non-labeled gentamicin congeners and synthetic methods for the preparation of such congeners. In particular, the present invention relates to isotope labeled gen...
|
|
WO/2024/077059A1 |
Described herein are crystalline forms of (M)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy-d2)-3'-flu
oro-2'-(3-(2-hydroxypropan-2-yl)-1H-pyrazol-1-yl)-5',6-dimet
hyl-2H-[1,4'-bipyridin]-2-one (compound 1), or a pharmaceutically accepta...
|
|
WO/2024/074813A1 |
The invention relates to a compound of the formula Xm-(Y-L-T)n and a method for the detection or prognosis of a disease in the exhaled breath of a subject. X, when present is a moiety operable to target the compound to a site of interest...
|
|
WO/2024/066981A1 |
Provided in the present invention are deuterated pyrazole derivatives, of which the structures are represented as formula (I). Further disclosed in the present invention are pharmaceutically acceptable salts and stereoisomers of the deri...
|
|
WO/2024/067503A1 |
The present application provides a composition and an organic electroluminescent device comprising same. The composition comprises two compounds represented by formula I and a compound represented by formula II; or the composition compri...
|
|
WO/2024/060356A1 |
The present invention relates to an economical and feasible method for industrially producing a deuterated COVID-19 medicament key intermediate D. The method has low reaction line cost, and high conversion rate, selectivity, reaction yie...
|
|
WO/2024/063095A1 |
The prevent invention provides a radiolabeled tyrosine derivative which has excellent LAT1 selectability, higher retention at a tumor or cancer site, and a degree of clearance that does not cause side effects, and which can be safely man...
|
|
WO/2024/064968A1 |
The present disclosure relates to the field of fibroblast activation protein (FAP) inhibitors, conjugates comprising the novel FAP inhibitors, including radiotracers, for the imaging, diagnosis and treatment of conditions characterized b...
|
|
WO/2024/057212A1 |
The present disclosure describes hyperpolarized materials for use in nuclear magnetic resonance, magnetic resonance imaging, or similar applications. The present disclosure describes methods for producing hyperpolarized materials for use...
|
|
WO/2024/059608A1 |
Provided herein is a deuterated compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R15a, R15b, R16a, R16b, R17, R18, R19, R21a,...
|
|
WO/2024/058665A1 |
The invention relates to the field of medicinal chemistry and radiopharmaceuticals, in particular to means, methods and cassettes for the automated synthesis of the radiotracer 6-L-[18F]fluoro-3,4- dihydroxyphenylalanine (6-L-[18F]FDOPA)...
|
|
WO/2023/247977A9 |
This invention relates to deuterated compounds useful in agriculture to treat diseases caused by oomycetes.
|
|
WO/2024/045292A1 |
The present invention relates to a method for catalytic industrial production of a deuterated pharmaceutical intermediate D by means of a combination of immobilized nickel and organic alkali. Reaction route conditions are mild, the conve...
|
|
WO/2024/049154A1 |
The present invention relates to a phenol compound substituted with a non-radioactive isotope and a use thereof, and more particularly, to a phenol compound in which some elements in biotin-phenol or desthiobiotin-phenol are substituted ...
|
|
WO/2024/037073A1 |
The present application belongs to the technical field of organic materials, and relates to a nitrogen-containing compound, an electronic element and an electronic device. The compound has a structure as shown in formula (1) below. The n...
|
|
WO/2024/036097A1 |
Provided herein are heteroaromatic macrocyclic ether compounds and isotopologues thereof, or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof, and methods of treating, preventing or man...
|
|
WO/2024/023332A1 |
The invention relates to novel silicon-based fluoride acceptor groups (SiFA groups) of the following formulae (Ia, Ib, Ic) as well as to compounds suitable for use in radiopharmacy comprising such groups, wherein R1 and R2 are each a lin...
|
|
WO/2024/020077A1 |
Disclosed are compounds, compositions, and methods useful for imaging cells in a subject. In particular, the compound have the structure of Formula (I) is useful in the dislocsed imaging methods:
|
|
WO/2024/014325A1 |
An aromatic compound configured from a stable isotope, wherein two adjacent carbon atoms are 13C, the nuclear spin quantum number of the other atoms to which the two adjacent carbon atoms bond is 0, and a hydrogen atom that has a spin co...
|
|
WO/2024/008075A1 |
Provided are a preparation method for a liquid composition containing compound I and a use in myocardial perfusion PET imaging, the method comprising the following step: purifying a crude product containing the compound I by using high-p...
|
|
WO/2024/007464A1 |
Disclosed is a method for producing a deuterated compound with a tower device. By means of using an active deuterium reagent as a deuterium source, the content of deuterium in the product is continuously improved in the absence of a cata...
|
|
WO/2024/008073A1 |
The present application provides a liquid composition of compound I, a preparation method therefor, and an application thereof, wherein same is selected from one or more among vitamin C, sodium ascorbate, and gentisic acid. By optimizing...
|
|
WO/2024/006582A1 |
Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron- emitting mannitol analogue, [18F]fluoromanni...
|
|
WO/2024/001967A1 |
The present invention relates to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, and in particular, to an imidazonaphthyridine compound with affinity with a Tau protein, a method for preparing same, an...
|
|
WO/2023/249989A1 |
Described herein are solid forms of 3-(((2S,3S)-8-methoxy-2-(6-methoxypyridin-3-yl)-3-methyl-2,3
-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-3H-imidazo[4,5-b]py
ridine-2-d, process of preparing the forms, pharmaceutical compositions, and me...
|
|
WO/2023/246829A1 |
A liquid composition comprising trans-2-(2-(5-(fluoro[ 18F])tridecyl)cyclopropyl)acetic acid, a preparation method therefor and use thereof in the preparation of a contrast agent for myocardial metabolic PET imaging. The liquid compositi...
|
|
WO/2023/247976A1 |
This invention relates to deuterated compounds useful in agriculture as herbicides.
|
|
WO/2023/246830A1 |
The present application provides a method for preparing a myocardial metabolism PET imaging agent, a liquid composition of trans-2-(2-(5-fluoro[18F]tridecyl)cyclopropyl)acetic acid (compound I for short), and use thereof, wherein a crude...
|
|
WO/2023/240849A1 |
Provided is a method for preparing a deuterated aromatic compound, the method comprising: taking an aromatic compound as a raw material, and under the protection of an inert atmosphere, subjecting same to a deuteration reaction in a solv...
|
|
WO/2023/240251A1 |
The present disclosure relates to crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-am
ine, salts thereof, pharmaceutical compositions thereof, pharmaceutical compositions comprising crystalline polymorp...
|
|
WO/2023/237091A1 |
The present application provides a device for producing a liquid composition of 2-tert-butyl-4-chloro-5-((3-((4-((2-(2-fluoro[18F]ethoxy)eth
oxy)methyl)-1H-1,2,3-triazole-1-yl)methyl)benzyl)oxy)pyridaz
ine-3(2H)-one (hereinafter referred...
|
|
WO/2023/235925A1 |
The present invention provides compounds of Formula (I), which have activity as inhibitors of MERTK. The present invention also provides radio-labelled compounds which may be used in diagnostic and imaging compositions. The present inven...
|
|
WO/2023/240205A1 |
The present disclosure provides deuterated compounds and their use as T-type calcium channel blockers in the treatment or prevention of various diseases or disorders associated with calcium T channels.
|
|
WO/2023/235734A1 |
The present disclosure provides deuterated compounds and their use as sodium channel blockers in the treatment or prevention of various diseases or disorders associated with sodium channels.
|
|
WO/2023/227996A1 |
The present invention relates to a process for synthesis of a deuterated compound. Most particularly, it relates to synthesis of a deuterated amine compounds of formula (l) and salts thereof. The said compound is an important key interme...
|
|
WO/2023/223050A1 |
The disclosures herein relate to methods of synthesising a compound of formula (1): (1) wherein PG, R2 and R3 are as defined herein, and the use of said methods in the manufacture of conjugates that bind to PSMA.
|
|
WO/2023/222559A1 |
The present invention relates to a process for preparing a deuterated organic compound, comprising the following steps: preparing a liquid composition comprising the organic compound, at least one heterogeneous metal catalyst, at least o...
|
|
WO/2023/222909A1 |
The inventors have now succeeded in developing arylsulfonium salts, in particular triarylsulfonium salts and dibenzothiophenium salts and a new use of said arylsulfonium salts. These compounds have the advantage of having a thioaryl grou...
|
|
WO/2023/219199A1 |
Disclosed are a manufacturing method for a FP-CIT precursor, and a manufacturing method for [18F]FP-CIT using a FP-CIT precursor manufactured thereby. The manufacturing method for a FP-CIT precursor, according to one embodiment of the pr...
|
|
WO/2023/213757A1 |
The present invention provides radiolabeled GABAA yl positive allosteric modulators (PAM) that are useful for medical imaging.
|
|
WO/2023/208023A1 |
The present disclosure relates to a deuterated chemical modification and an oligonucleotide including same. Specifically, the present disclosure relates to an oligonucleotide including a chemical modification represented by formula (I) o...
|
|
WO/2023/209028A1 |
The invention relates to sulphonyl benzene derivatives, in particular to fluorinated sulphonyl benzene derivatives. It is provided a compound of formula (I) or general formula (IA) wherein X is fluorine; A is either O or NH; B is an amin...
|
|
WO/2023/205908A1 |
The present application provides a synthetic process for production of lipoxin B4 and analogues thereof, which is modular and scalable, thus permitting synthesis of large quantities of LXB4 and analogues thereof, including radiolabeled a...
|
|
WO/2023/205701A1 |
The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, t...
|
|
WO/2023/202568A1 |
Disclosed in the present invention are a quaternary ammonium salt compound, and a preparation method therefor and an application thereof. The general formula of the quaternary ammonium salt compound in the present invention is as follows...
|
|
WO/2023/198873A1 |
The application relates to isoxazolyl-pyrazole derivatives of the general formula (I) for the treatment of diseases and conditions such as psoriasis, autoimmune thyroiditis, inflammatory bowel disease and cancer in which inverse agonism ...
|
|
WO/2023/194360A1 |
The present invention relates to a process for producing a isotopically labelled organic compound or a mixture of such compounds in a gas-fed zero-gap electrolyser device.
|
|
WO/2023/182469A1 |
The present invention provides, as a technique that is applicable to the production of a methylphenol from biomass, a method for producing a methylphenol, the method comprising a step in which a methyl tyrosine is converted into a methyl...
|
|
WO/2023/174709A1 |
The present invention is directed to 13C-labelled chlorinated paraffins, preferably having neither geminal nor terminal chlorine atoms in their structure, processes for their preparation as well as their uses.
|
